Trial Profile
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Cancer pain
- Focus Registrational; Therapeutic Use
- Acronyms SPRAY-III
- Sponsors Jazz Pharmaceuticals Inc
- 08 Jan 2015 Top-line results published in a GW Pharmaceuticals media release.
- 08 Jan 2015 Primary endpoint has not been met (percent improvement in mean pain score from baseline to end of treatment, evaluated by patients using a 0 to 10 numeric rating scale), according to a GW Pharmaceuticals media release.
- 17 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.